Regeneron Increases Stake In ISA Pharma, Plans Pivotal Study
Third Study Planned Under Clinical Collaboration
ISA Pharmaceuticals and Regeneron have updated their collaboration to outline a potential path to market for a combination of an anticancer immunotherapeutic and the checkpoint inhibitor, cemiplimab, for HPV-associated head-and-neck cancer.
You may also be interested in...
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.